The impact of oculomotor functioning on neuropsychological performance in Huntington disease

ABSTRACT Huntington disease (HD) is a neurodegenerative condition with prominent motor (including oculomotor), cognitive, and psychiatric effects. While neuropsychological deficits are present in HD, motor impairments may impact performance on neuropsychological measures, especially those requiring a speeded response, as has been demonstrated in multiple sclerosis and schizophrenia. The current study is the first to explore associations between oculomotor functions and neuropsychological performance in HD. Participants with impaired oculomotor functioning performed worse than those with normal oculomotor functioning on cognitive tasks requiring oculomotor involvement, particularly on psychomotor speed tasks, controlling for covariates. Consideration of oculomotor dysfunction on neuropsychological performance is critical, particularly for populations with motor deficits.

[1]  P. Allison,et al.  Missing data , 2005, European Radiology.

[2]  Jane S. Paulsen,et al.  Movement sequencing in Huntington disease , 2014, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[3]  Jane S. Paulsen,et al.  Tracking motor impairments in the progression of Huntington's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[4]  John O. Willis,et al.  Wechsler Abbreviated Scale of Intelligence , 2014 .

[5]  Jane S. Paulsen,et al.  Cognitive decline in prodromal Huntington Disease: implications for clinical trials , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  Geert Molenberghs,et al.  The gradient function as an exploratory goodness-of-fit assessment of the random-effects distribution in mixed models. , 2013, Biostatistics.

[7]  Jane S. Paulsen,et al.  Cognitive domains that predict time to diagnosis in prodromal Huntington disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  Jane S. Paulsen,et al.  CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion , 2012, Neurology.

[9]  Jane S. Paulsen,et al.  Indexing disease progression at study entry with individuals at‐risk for Huntington disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[10]  T. Turner,et al.  Behavioral Measures of Saccade Latency and Inhibition in Manifest and Premanifest Huntington's Disease , 2011, Journal of Motor Behavior.

[11]  J. Corey-Bloom,et al.  A randomized, placebo-controlled trial of latrepirdine in Huntington disease. , 2010, Archives of neurology.

[12]  Jennifer Goldman,et al.  Huntington disease , 2010, Principles and Practice of Movement Disorders.

[13]  Jane S. Paulsen,et al.  Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[14]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[15]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  F. Richer,et al.  Episodic memory impairment in Huntington's disease: A meta-analysis , 2006, Neuropsychologia.

[17]  X. Beristain,et al.  Saccades in presymptomatic and early stages of Huntington disease , 2006, Neurology.

[18]  C. Kennard,et al.  Identification of an oculomotor biomarker of preclinical Huntington disease , 2006, Neurology.

[19]  D. Langbehn,et al.  Preparing for Preventive Clinical Trials , 2006, Archives of Neurology.

[20]  Julie C Stout,et al.  Cognitive impairment and dementia in basal ganglia disorders , 2005, Current neurology and neuroscience reports.

[21]  Jane S. Paulsen,et al.  White Matter Volume and Cognitive Dysfunction in Early Huntington's Disease , 2005, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[22]  R. Yee,et al.  Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington’s disease , 2003, Vision Research.

[23]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .

[24]  J. Harbison,et al.  The Neurology of Eye Movements, 3rd ed , 2000 .

[25]  S. Dursun,et al.  The effects of antipsychotic medication on saccadic eye movement abnormalities in Huntington's disease , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  Nick Fogt,et al.  The Neurology of Eye Movements, 3rd ed. , 2000 .

[27]  Jane S. Paulsen,et al.  Rate of functional decline in Huntington’s disease , 2000, Neurology.

[28]  D. Zee,et al.  Ocular motor abnormalities in Huntington's disease , 1997, Vision Research.

[29]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[30]  A. Radant,et al.  Relationships between Neuropsychological and Oculomotor Measures in Schizophrenia Patients and Normal Controls , 1997, Biological Psychiatry.

[31]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[32]  J. Brandt,et al.  Self-selection in predictive testing for Huntington's disease. , 1994, American journal of medical genetics.

[33]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[34]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[35]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[36]  S. R. Max.  Animal models of dementia: A synaptic neurochemical perspective Neurology and neurobiology, vol. 33. Edited by Joseph T. Coyle. ISBN 08-451-273-49, Alan R. Liss, New York, 1987. , 1988, Neurochemistry International.

[37]  M. D. Sanders.  The Neurology of Eye Movements , 1984 .

[38]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[39]  Eric H Kim,et al.  The Neuropathology of Huntington's Disease. , 2015, Current topics in behavioral neurosciences.

[40]  Jane S. Paulsen,et al.  Neurocognitive signs in prodromal Huntington disease. , 2011, Neuropsychology.

[41]  Jane S. Paulsen.  Early Detection of Huntington Disease. , 2010, Future neurology.

[42]  Christopher Kennard,et al.  Oculomotor deficits indicate the progression of Huntington's disease. , 2008, Progress in brain research.

[43]  D. Langbehn,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[44]  Jane S. Paulsen,et al.  Cognitive changes in Huntington's disease. , 2005, Advances in neurology.

[45]  D. Rubinsztein.  Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders , 2003 .

[46]  J. Ridley.  Studies of Interference in Serial Verbal Reactions , 2001 .

[47]  H. Kremer.  Unified Huntington's disease rating scale: reliability and consistency , 1996 .